What question did this study set out to answer?

To assess and compare postmarketing reports of fatal rhabdomyolysis associated with six statin therapies following the withdrawal of cerivastatin.

February 14, 2002New England Journal of MedicineOpen Access

Cerivastatin and Reports of Fatal Rhabdomyolysis

View Full Paper

Ask AI

Bookmark

Population

U.S. reports of fatal rhabdomyolysis associated with statins in the Adverse Event Reporting System

Design

Editorial

Authors

JSJudy A. StaffaCenter for Drug Evaluation and Research JCJennie ChangUnited States Food and Drug Administration LGLanh GreenUnited States Food and Drug Administration

Discussion

Member takes

Implication

This letter summarizes U.S. reports of fatal rhabdomyolysis associated with statin therapy, highlighting the safety risks of cerivastatin and concomitant use of interacting drugs.

Key Points

To assess and compare postmarketing reports of fatal rhabdomyolysis associated with six statin therapies following the withdrawal of cerivastatin.
Reviewed fatal adverse drug reaction reports submitted to the U.S. Adverse Event Reporting System.
Analyzed reports for six statin agents: lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and cerivastatin, including co-prescription with gemfibrozil.
Fatal rhabdomyolysis occurred across all six evaluated statin drugs, with cerivastatin showing a markedly disproportionate number of fatal reports.
Concomitant administration with interacting drugs like gemfibrozil significantly heightened the risk of fatal muscle toxicity across statin regimens.

Structured PICO

Population

U.S. reports of fatal rhabdomyolysis associated with statins in the Adverse Event Reporting System

Intervention

Statins (lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and cerivastatin)

Outcome

Fatal rhabdomyolysissafety

This letter summarizes U.S. reports of fatal rhabdomyolysis associated with statin therapy, highlighting the safety risks of cerivastatin and concomitant use of interacting drugs.

Cite This Study

Staffa et al. (2002) studied this question.

synapsesocial.com/papers/6a736b7f644e61a44f4e5bdd https://doi.org/10.1056/nejm200202143460721

Topics

Statin therapy

View Full Paper

Ask AI

Bookmark

Implication

This letter summarizes U.S. reports of fatal rhabdomyolysis associated with statin therapy, highlighting the safety risks of cerivastatin and concomitant use of interacting drugs.

Cerivastatin and Reports of Fatal Rhabdomyolysis

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Cerivastatin and Reports of Fatal Rhabdomyolysis

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider